Zacks Investment Research upgraded shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a hold rating to a buy rating in a research note published on Wednesday morning. They currently have $4.00 price objective on the medical research company’s stock.
According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
Several other equities analysts also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a research report on Wednesday, November 8th. ValuEngine raised HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity boosted their target price on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $5.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings data on Tuesday, November 7th. The medical research company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.03. equities analysts forecast that HTG Molecular Diagnostics will post -1.92 earnings per share for the current fiscal year.
An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA increased its stake in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 416,608 shares of the medical research company’s stock after purchasing an additional 345,798 shares during the quarter. Granahan Investment Management Inc. MA owned 3.33% of HTG Molecular Diagnostics worth $708,000 at the end of the most recent quarter. Institutional investors own 15.15% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.